{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:24:45Z","timestamp":1791548685580,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.semarthrit.2015.02.004","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T19:47:41Z","timestamp":1424375261000},"page":"75-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["The economic burden of gout: A systematic review"],"prefix":"10.1016","volume":"45","author":[{"given":"Sharan K.","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay C.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"De Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Haji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Giustini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.02.004_bib1","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib3","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/rheumatology\/kep087","article-title":"Treating to target: a strategy to cure gout","volume":"48","author":"Perez-Ruiz","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrrheum.2014.32","article-title":"Optimizing current treatment of gout","volume":"10","author":"Rees","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib5","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part II: therapy and anti-inflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib6","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22336","article-title":"Medication adherence in gout: a systematic review","volume":"66","author":"De Vera","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib8","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib9","first-page":"104","article-title":"Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study","volume":"33","author":"Neogi","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib10","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0149-2918(03)80158-3","article-title":"A literature review of the epidemiology and treatment of acute gout","volume":"25","author":"Kim","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2013.04.003","article-title":"A revised estimate of the burden of illness of gout","volume":"75","author":"Wertheimer","year":"2013","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/11588380-000000000-00000","article-title":"Cost-of-illness studies: a guide to critical evaluation","volume":"29","author":"Larg","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib13","series-title":"Cost-effectiveness in health and medicine","author":"Gold","year":"1996"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib14","unstructured":"Segel JE, Cost-of-illness studies-a primer, RTI-UNC Center of Excellence in Health Promotion Economics. RTI International, 2006:1\u201339."},{"key":"10.1016\/j.semarthrit.2015.02.004_bib15","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3899\/jrheum.080768","article-title":"Gout in the elderly\u2014a population health study","volume":"36","author":"Hanly","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.archger.2010.04.017","article-title":"The prevalence of chronic conditions and medical expenditures of the elderly by chronic condition indicator (CCI)","volume":"52","author":"Chi","year":"2011","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib17","first-page":"94","article-title":"Resource use and economic impact of patients with gout: a multicenter, population-wide study","volume":"9","author":"Sicras-Mainar","year":"2013","journal-title":"Rheumatol Clin"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib18","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.080487","article-title":"Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?","volume":"36","author":"Wu","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","article-title":"The effect of serum urate on gout flares and their associated costs: an administrative claims analysis","volume":"15","author":"Halpern","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib20","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1185\/030079906X112606","article-title":"The economic burden of gout on an employed population","volume":"22","author":"Brook","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib21","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/MJT.0b013e31820543c5","article-title":"Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy","volume":"19","author":"Wu","year":"2012","journal-title":"Am J Ther"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.18553\/jmcp.2008.14.2.164","article-title":"Disease-related and all-cause health care costs of elderly patients with gout","volume":"14","author":"Wu","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/pop.2012.0057","article-title":"Economic burden of gouty arthritis attacks for employees with frequent and infrequent attacks","volume":"16","author":"Lynch","year":"2013","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib24","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/rheumatology\/kes183","article-title":"Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks","volume":"51","author":"Saseen","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib25","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.clinthera.2012.01.020","article-title":"Evaluation of health care costs and utilization patterns for patients with gout","volume":"34","author":"Park","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib26","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1185\/03007990903017966","article-title":"Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis","volume":"25","author":"Halpern","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/acr.21837","article-title":"Gout-related health care utilization in US emergency departments, 2006 through 2008","volume":"65","author":"Garg","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib28","first-page":"e46","article-title":"Ambulatory resource utilization and cost for gout in United States","volume":"5","author":"Li","year":"2013","journal-title":"Am J Pharm Benefits"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3111\/13696998.2010.540874","article-title":"Work productivity loss due to flares in patients with chronic gout refractory to conventional treatment","volume":"14","author":"Edwards","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","article-title":"Gout epidemiology: results from the UK General Practice Research Database, 1990\u20131999","volume":"64","author":"Mikuls","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.22466","article-title":"Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey","volume":"57","author":"Choi","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/1529-0131(199906)42:6<1209::AID-ANR18>3.0.CO;2-M","article-title":"An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline","volume":"42","author":"Yelin","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.02.004_bib33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/JOM.0b013e318282d310","article-title":"Annual incremental health benefit costs and absenteeism among employees with and without rheumatoid arthritis","volume":"55","author":"Kleinman","year":"2013","journal-title":"J Occup Environ Med"},{"issue":"Suppl. 73","key":"10.1016\/j.semarthrit.2015.02.004_bib34","first-page":"S145","article-title":"The economic impact of gout: a systematic literature review","volume":"30","author":"Trieste","year":"2012","journal-title":"Clin Exp Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T08:49:33Z","timestamp":1620809373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0049017215000141"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.02.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The economic burden of gout: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}